User login
Over the last 15 years the treatment of psoriasis has been transformed with the advent of biologic agents. Now we have a whole new generation of treatments that is emerging. With all of these therapeutic options, the dermatologic community is in need of increasing data to help us further understand both the therapies and the disease state.
A new independent US psoriasis registry has been established. This registry is a joint collaboration with the National Psoriasis Foundation and Corrona, Inc (Consortium of Rheumatology Researchers of North America, Inc). Data will be gathered through comprehensive questionnaires completed by patients and their dermatologists during appointments.
The registry will function to collect and analyze clinical data, and thereby allow investigators to achieve the following: (1) compare the safety and effectiveness of psoriasis treatments, (2) better understand psoriasis comorbidities, and (3) explore the natural history of the disease.
The registry will begin recruiting patients this year. Initially, the registry will track the drug safety reporting for secukinumab. The goal is for the CORRONA psoriasis registry to enroll at least 3000 patients with psoriasis who are taking secukinumab and then follow their treatment for at least 8 years.
In addition to studying safety and effectiveness of therapeutics, the registry also will help identify potential etiologies of psoriasis, study the relationship between psoriasis and other health conditions, and examine the impact of the condition on quality of life, among other outcomes.
To become an investigator in the registry or learn more about it, visit www.psoriasis.org/corrona-registry.
What’s the issue?
This registry is a welcomed addition to the study of psoriasis. It has the potential to add critical information in the years to come.
Over the last 15 years the treatment of psoriasis has been transformed with the advent of biologic agents. Now we have a whole new generation of treatments that is emerging. With all of these therapeutic options, the dermatologic community is in need of increasing data to help us further understand both the therapies and the disease state.
A new independent US psoriasis registry has been established. This registry is a joint collaboration with the National Psoriasis Foundation and Corrona, Inc (Consortium of Rheumatology Researchers of North America, Inc). Data will be gathered through comprehensive questionnaires completed by patients and their dermatologists during appointments.
The registry will function to collect and analyze clinical data, and thereby allow investigators to achieve the following: (1) compare the safety and effectiveness of psoriasis treatments, (2) better understand psoriasis comorbidities, and (3) explore the natural history of the disease.
The registry will begin recruiting patients this year. Initially, the registry will track the drug safety reporting for secukinumab. The goal is for the CORRONA psoriasis registry to enroll at least 3000 patients with psoriasis who are taking secukinumab and then follow their treatment for at least 8 years.
In addition to studying safety and effectiveness of therapeutics, the registry also will help identify potential etiologies of psoriasis, study the relationship between psoriasis and other health conditions, and examine the impact of the condition on quality of life, among other outcomes.
To become an investigator in the registry or learn more about it, visit www.psoriasis.org/corrona-registry.
What’s the issue?
This registry is a welcomed addition to the study of psoriasis. It has the potential to add critical information in the years to come.
Over the last 15 years the treatment of psoriasis has been transformed with the advent of biologic agents. Now we have a whole new generation of treatments that is emerging. With all of these therapeutic options, the dermatologic community is in need of increasing data to help us further understand both the therapies and the disease state.
A new independent US psoriasis registry has been established. This registry is a joint collaboration with the National Psoriasis Foundation and Corrona, Inc (Consortium of Rheumatology Researchers of North America, Inc). Data will be gathered through comprehensive questionnaires completed by patients and their dermatologists during appointments.
The registry will function to collect and analyze clinical data, and thereby allow investigators to achieve the following: (1) compare the safety and effectiveness of psoriasis treatments, (2) better understand psoriasis comorbidities, and (3) explore the natural history of the disease.
The registry will begin recruiting patients this year. Initially, the registry will track the drug safety reporting for secukinumab. The goal is for the CORRONA psoriasis registry to enroll at least 3000 patients with psoriasis who are taking secukinumab and then follow their treatment for at least 8 years.
In addition to studying safety and effectiveness of therapeutics, the registry also will help identify potential etiologies of psoriasis, study the relationship between psoriasis and other health conditions, and examine the impact of the condition on quality of life, among other outcomes.
To become an investigator in the registry or learn more about it, visit www.psoriasis.org/corrona-registry.
What’s the issue?
This registry is a welcomed addition to the study of psoriasis. It has the potential to add critical information in the years to come.
